SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmuLogic
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Paul Getman who wrote (6)9/23/1996 7:44:00 PM
From: Paul Getman   of 23
 
A new research report on IMUL has been issued by Punk Ziegel & Knoell. They repeat their Buy recommendation and have a 1997 target price for IMUL of $18.

IMUL is now done with its dosing for the Allervax Ragweed trial. 500 patients have been enrolled, each in one of five groups. One group received 4 injections of Allervax 750ug twice weekly for two weeks (2x2); a second group received placebo 2x2; the third and fourth groups received eight injections of either Allervax or placebo at 250uq every other day for three weeks (3-4x3); and the fifth group received no injections.

This latter group will allow IMUL to better control for the placebo effect that has haunted them this year. IMUL explicitly informed patients that there was only a 40% probability of receiving Allervax Ragweed. This is the new part of the trial that was designed with the FDA's input.

The Punk, Ziegel report notes that data from IMUL's Allervax Cat trial showed that more severe allergy patients responded better than the mildly affected ones and that the placebo response for this group was significantly diminished. Based on this data, IMUL excluded non-responders and patients with low allergy skin test scores from their Allervax Ragweed trial.

No news yet on potential partners to replace HMR.

Paul
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News